Nov 13 (Reuters) - The U.S. Food and Drug Administration approved PTC Therapeutics' (PTCT.O), opens new tab gene ... new ...

Joseph Schwartz, an analyst from Leerink Partners, reiterated the Hold rating on PTC Therapeutics (PTCT – Research Report). The ...

Barclays raised the firm’s price target on PTC Therapeutics (PTCT) to $43 from $31 and keeps an Equal Weight rating on the shares. The ...

Tampa Bay forecasters say it’s too early to tell where the storm will go, but urged residents to keep an eye on forecasts.

Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock Oppenheimer has initiated coverage on Larimar Therapeutics ...

BOSTON (AP) — BOSTON (AP) — PTC Inc. (PTC) on Wednesday reported fiscal fourth-quarter earnings of $126.5 million. The Boston-based company said it had net income of $1.04 per share.

Nov 6 (Reuters) - Industrial software maker PTC (PTC.O), opens new tab forecast first-quarter revenue below estimates on Wednesday, signaling continued weakness in demand for its industrial design ...

For the quarter, PTC anticipates revenues to be between $598 million and $648 million. Non-GAAP earnings per share (EPS) are expected to be between $1.30 and $1.66. The Zacks Consensus Estimate ...

The biopharmaceutical company posted revenue of $196.8 million in the period, also beating Street forecasts. Five analysts surveyed by Zacks expected $173.5 million. PTC Therapeutics expects full-year ...

PTC Therapeutics Says FDA Lifts Clinical Hold On Investigational Study In Patients With Rare Weak Nerve Cell Disorder PTC Therapeutics released interim results from its Phase 2 PIVOT-HD study on ...